All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for ELI LILLY & COMPANY · Pharmaceutical/ Health Products

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Apr 21, 2025

Official filing document

Lobbying activity 6

Taxation/Internal Revenue Code

International and domestic tax issues.

Health Issues

General education about policies impacting pharmaceutical development, approval and reimbursement. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, 340B Program. "Inflation Reduction Act of 2022" (PL 117-169). Accelerated Approval pathway; Alzheimers diagnostics policies. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023.

Medicare/Medicaid

Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023.

Budget/Appropriations

Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment.

Trade (domestic/foreign)

Issues related to pharmaceutical manufacturing and development.

Defense

Issues related to pharmaceutical manufacturing and development.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.